Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor versus clopidogrel plus aspirin after CABG
ChiCTR1900022390Phase 4Recruiting
- Sponsor
- Dalian Municipal Central Hospital
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor, clopidogrel and aspirin in coronary arteriosclerosis (2 arms), sponsored by Dalian Municipal Central Hospital. Primary endpoints: Graft patency and Major adverse cardiovascular events. Started Apr 2019; status: recruiting.
02
Drugs
ticagrelorclopidogrelaspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900022390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022390.